,8 Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) have reported that monthly dosing of anti-VEGF had a higher hazard ratio for GA development than pro re nata injections.35 This evidence concerns the gene VEGFA and age-related macular degeneration.